Global Single Domain Antibody(sdAbs) Drugs Market Strategic Research Report

Scope of the Report

The global Single Domain Antibody(sdAbs) Drugs market size is predicted to grow from US$ 491 million in 2025 to US$ 1,119 million in 2032; it is expected to grow at a CAGR of 12.3% from 2026 to 2032.

Single Domain Antibody Drugs refer to approved and commercially marketed therapeutic drugs whose active molecules are based on single-domain antibody structures. The currently marketed products mainly include Sanofi's Cablivi, Taisho Pharmaceutical's Nanozora, and Envafolimab manufactured by Alphamab Oncology, covering indications such as acquired thrombotic thrombocytopenic purpura, rheumatoid arthritis, and selected advanced solid tumors. Key upstream inputs include engineered expression cell lines, cell culture media, feeds, single-use bioreactor consumables, chromatography resins, ultrafiltration membranes, buffers, sterile filling components, vials or prefilled syringes, stoppers, labels, and cold-chain packaging materials. Major downstream customers include hospitals, specialty treatment centers, oncology departments, hematology departments, rheumatology and immunology departments, pharmaceutical distributors, and public or commercial reimbursement systems. The 2025 global nominal production capacity is estimated at approximately 1.25 million units, actual sales volume at about 728,000 units, average ex-factory price at around USD 690 per unit, and industry gross margin at approximately 68%–82%.

The single-domain antibody drug market is currently in an early commercialization phase, with clear technological advantages but a limited number of marketed products. Existing drugs mainly target rare diseases, rheumatology, and oncology, showing a small-product, high-margin, and highly differentiated market profile. Differences in indications, administration methods, and patient populations create a dispersed yet finely segmented market structure. As indications expand and more candidate drugs gain approval, the market is expected to gradually grow, although near-term expansion remains centered on currently marketed products and is constrained by regulatory approval and hospital access timelines. The global competitive landscape is highly concentrated, with major manufacturers holding technological barriers and patent protections that confer first-mover advantages. Sanofi, Alphamab Oncology, and Taisho Pharmaceutical occupy leading positions in hematology, oncology immunotherapy, and rheumatology, respectively. New entrants face long R&D timelines, clinical validation requirements, and regulatory hurdles, limiting their ability to capture market share in the short term. Competition focuses on product differentiation, clinical application expansion, and production and supply capabilities, with the commercial model revolving around a small number of high-value patients. Future market growth will be driven by indication expansion of marketed products, regional market access, improvements in reimbursement systems, and potential new drug approvals. The structural characteristics of single-domain antibodies provide advantages in subcutaneous administration, tissue penetration, and multispecific design, potentially increasing penetration in rare diseases and specialized oncology immunotherapy. Technological integration, including AI-assisted discovery, high-throughput screening, and optimization platforms, is expected to improve candidate selection efficiency and developability, supporting market expansion. Key barriers remain the limited number of marketed products, narrow indications, long clinical development cycles, strict regulatory requirements, and small patient populations. Some drugs are derived from non-human structures and require humanization and immunogenicity validation. Although single-domain antibodies offer high technological barriers and innovation value, near-term market expansion is limited, and revenue growth depends on market penetration of existing products, indication expansion, and execution capabilities. Overall, market growth is steady but concentrated in a few core products and manufacturers.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Single Domain Antibody(sdAbs) Drugs market?

What factors are driving Single Domain Antibody(sdAbs) Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Single Domain Antibody(sdAbs) Drugs market opportunities vary by end market size?

How does Single Domain Antibody(sdAbs) Drugs break out by Type, by Application?

This report presents a comprehensive overview of the global Single Domain Antibody(sdAbs) Drugs market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Cablivi
• Nanozora
• Envafolimab

Segment by Administration Route

• Subcutaneous Injection
• Intravenous Injection
• Other

Segment by Sales Channels

• Online Sales
• Offline Sales

Segment by Application

• Hospital
• Clinic
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Single Domain Antibody(sdAbs) Drugs market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital, Clinic, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact